(Albany, USA) DelveInsight’s “Triple Negative Breast Cancer Pipeline Insight 2025” report provides comprehensive insights about 165+ companies and 170+ pipeline drugs in the Triple Negative Breast Cancer pipeline landscape. It covers the Triple Negative Breast Cancer Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Triple Negative Breast Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
As per DelveInsight, the Triple Negative Breast Cancer therapeutics market is anticipated to evolve immensely in the coming years owing to the increasing incident population of TNBC patients, the improvement in the diagnosis methodologies, rising awareness of the disease, incremental healthcare spending worldwide, and the launch of new therapies in the market.
Upcoming therapies, such as TECENTRIQ (Hoffmann-La Roche), IPI-549 (Infinity Pharmaceuticals), Leronlimab (CytoDyn), MDNA11 (Medicenna Therapeutics), VIP236 (Vincerx Pharma), and CFI-400945 (Treadwell Therapeutics), and others, have the potential to create a significant positive shift in the TNBC market size and the treatment scenario.
To know more about the TNBC pipeline Report offerings and trends, request for a free sample report @ Triple Negative Breast Cancer Drug Pipeline Analysis
Key Takeaways from the Triple Negative Breast Cancer Pipeline Report
Stay ahead with the most recent pipeline outlook for Triple Negative Breast Cancer. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Triple Negative Breast Cancer Treatment Drugs
Triple Negative Breast Cancer Emerging Drugs
TofaciTrilaciclib, a transient IV-administered CDK4/6 inhibitor, is a novel therapeutic approach which is given before chemotherapy that temporarily blocks progression through the cell cycle. This provides two potential benefits firstly bone marrow protection and therefore the immune system from damage caused by cytotoxic therapy, and secondly improved long term immune surveillance by upregulating the formation of certain memory T cells. Trilaciclib is being evaluated a number of tumor types and chemotherapy regimens to assess its potential myeloprotection, antitumor efficacy and safety in combination with cytotoxic therapies and other anticancer agents. Currently, the drug is in the Phase III stage of its development for the treatment of Triple Negative Breast Cancer.
Olaparib is an oral PARP inhibitor developed by AstraZeneca, approved for BRCA-mutated triple-negative breast cancer (TNBC). It works by blocking PARP enzymes, preventing DNA repair in cancer cells, leading to cell death, particularly in BRCA1/2-mutant tumors. The OlympiAD trial showed that Olaparib significantly improved progression-free survival (PFS) compared to chemotherapy in metastatic TNBC. It is FDA-approved for germline BRCA-mutated, HER2-negative breast cancer and is being explored in combination with immunotherapy and chemotherapy for broader TNBC treatment. Currently, the drug is in the Phase II/III stage of its development for the treatment of Triple Negative Breast Cancer.
Patritumab deruxtecan (HER3-DXd) is an investigational HER3-directed antibody–drug conjugate (ADC) developed by Daiichi Sankyo. It comprises a fully human anti-HER3 monoclonal antibody linked to a topoisomerase I inhibitor payload via a tumor-selective cleavable linker. HER3 is frequently overexpressed in triple-negative breast cancer (TNBC), correlating with poorer prognosis. In a phase 1/2 trial, patritumab deruxtecan demonstrated promising clinical activity in patients with HER3-expressing metastatic breast cancer. Currently, the drug is in the Phase II stage of its development for the treatment of Triple Negative Breast Cancer.
NUV-868 is an experimental drug being studied alone and in combination with PARP inhibitors for the treatment of advanced solid tumors, including triple-negative breast cancer (TNBC). Nuvation Bio had decided not to initiate a Phase II study of NUV-868 as a monotherapy or in combination with olaparib or enzalutamide in the advanced solid tumor indications that were part of the Phase I and Phase Ib study designs. The Company is evaluating next steps for the NUV-868 program, including further development in combination with approved products for indications in which BD2-selective BET inhibitors may improve outcomes for patients. Currently, the drug is in the Phase I/II stage of its development for the treatment of Triple Negative Breast Cancer.
TUB-030 is an antibody drug conjugate directed against 5T4, an oncofetal antigen, expressed in a broad range of solid tumor types. It consists of an IgG1 antibody targeting 5T4 connected to the Topoisomerase I inhibitor exatecan through a cleavable linker system based on the company’s proprietary P5 conjugation technology with a homogeneous DAR of 8. P5 conjugation is a novel chemistry for cysteine-selective conjugation that enables ADC generation with unprecedented linker stability and biophysical properties. Currently the drug is in Preclinical stage of its development for the treatment of TNBC.
The Triple Negative Breast Cancer Pipeline report provides insights into
Explore groundbreaking therapies and clinical trials in the Triple Negative Breast Cancer Pipeline. Access DelveInsight’s detailed report now! @ New Triple Negative Breast Cancer Drugs
Triple Negative Breast Cancer Companies
G1 Therapeutics, Inc, Gilead Sciences, Biotheus Inc., GlaxoSmithKline, Hoffmann-La Roche, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical, Shanghai Escugen Biotechnology, AstraZeneca, Jiangsu Hengrui Medicine, Sichuan Baili Pharmaceutical, Novartis Pharmaceuticals, Akeso Biopharma, OBI Pharma, Shanghai Jiaolian Drug Research and Development Co., Ltd, Coherent Biopharma, Daiichi Sankyo Company/Merck, SynDevRx, Inc., Treadwell Therapeutics, Merck & Co, BeBetter Med, Tasly Biopharmaceuticals Co., Ltd., Ambrx, Eli Lilly and Company, Rhizen Pharmaceuticals, Roche, TJ Biopharma Co., Ltd., Prolynx, Merck Sharp & Dohme LLC, ES-102; Hexavalent OX40 agonist antibody, INBRX-106, Processa Pharmaceuticals, Oncolytics Biotech, OncoSec Medical Incorporated, PharmAbcine, JenKem Technology, MedSIR, Zenith Epigenetics, Astellas Pharma Inc, Intensity Therapeutics, Inc., NEC Corporation, Cardiff Oncology, Ocellaris Pharma, Inc., Nuvation Bio Inc., NeoImmuneTech, Scancell Ltd, Lantern Pharma Inc., Medicenna Therapeutics, Inc., Jiangsu Alphamab Biopharmaceuticals Co., Ltd, Salubris Biotherapeutics Inc, Pfizer/Merck, Celcuity Inc., Jacobio Pharmaceuticals Co., Ltd., Immunitas Therapeutics, Innolake Biopharm, Hummingbird Bioscience, Hutchmed/BeiGene, Adagene Inc, Genmab, ProDa BioTech, Rapa Therapeutics LLC, Amgen, Strand Therapeutics Inc., Simcha Therapeutics, UCB, Sumitomo Pharma America, Inc., Shanghai Junshi Biosciences, Abbisko Therapeutics, Cytovation AS, CytosinLab Therapeutics Co., Ltd., Cantargia AB, BioAtla, Inc., BicycleTx Limited, Transgene, Bristol-Myers Squibb, BioLite, Inc., Bolt Biotherapeutics, Inc., Avenzo Therapeutics, Inc., Apollo Therapeutics Ltd, A2 Biotherapeutics Inc., Fusion Pharmaceuticals Inc., Volastra Therapeutics, Inc., Teon Therapeutics, Inc., TransThera Sciences (Nanjing), Inc., TCR2 Therapeutics, NeoTX Therapeutics Ltd., Phoenix Molecular Designs, Pure Biologics S.A., Mersana Therapeutics, Zumutor Biologics Inc., Xencor, Inc., Janux Therapeutics, Memgen, Inc., ModernaTX, Inc., Myeloid Therapeutics, Nanobiotix, NiKang Therapeutics, Inc., Numab Therapeutics AG, NextPoint Therapeutics, Inc., Nurix Therapeutics, Inc., Imugene Limited, OncoNano Medicine, Inc., Tizona Therapeutics, Inc, Theratechnologies, Exelixis, MBrace Therapeutics, LIGACHEM BIOSCIENCES Inc., Bellicum Pharmaceuticals, Compass Therapeutics, Circle Pharma, AbbVie, Adcentrx Therapeutics, Angiex, Inc., Precigen, Inc, Novartis, Laekna Limited, Light Chain Bioscience – Novimmune SA, BeiGene, SillaJen, Inc., Genentech, Inc., Accent Therapeutics, Arcus Biosciences, Inc., A2A Pharmaceuticals Inc., Adlai Nortye Biopharma Co., Ltd., Sichuan Baili Pharmaceutical Co., Ltd., Compugen Ltd, BioEclipse Therapeutics, Innate Pharma, ImmunoGenesis, Tubulis GmbH, Hinova pharmaceuticals, Repertoire Immune Medicines, VEANA THERAPEUTICS, Pharos iBio Co., Ltd., GeneQuantum Healthcare, Trio Pharmaceuticals, Cellectis, Rakovina Therapeutics, Pan Cancer T, Pinotbio, Starlight Therapeutics, Primevax, ARCE therapeutics, HC Biopharma, Casinvent, Speer Medical Technologies, Shengjing Hospital, others.
Triple Negative Breast Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Triple Negative Breast Cancer Products have been categorized under various Molecule types such as
Unveil the future of Triple Negative Breast Cancer Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight’s expert analysis @ Triple Negative Breast Cancer Market Drivers and Barriers
Scope of the Triple Negative Breast Cancer Pipeline Report
Get the latest on Triple Negative Breast Cancer Therapies and clinical trials. Download DelveInsight’s in-depth pipeline report today! @ Triple Negative Breast Cancer Companies, Key Products and Unmet Needs
Table of Content
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Ankit NigamEmail: Send EmailPhone: +14699457679Address:304 S. Jones Blvd #2432 City: AlbanyState: New YorkCountry: United StatesWebsite: https://www.delveinsight.com/consulting/competitive-intelligence-services
